Equities

Shanghai Serum Bio-Technology Co Ltd

688163:SHH

Shanghai Serum Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)15.20
  • Today's Change-5.31 / -25.89%
  • Shares traded1.36m
  • 1 Year change-29.99%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments874933181
Total Receivables, Net238.6616
Total Inventory455549
Prepaid expenses7.240.511.89
Other current assets, total------
Total current assets949997248
Property, plant & equipment, net128117105
Goodwill, net------
Intangibles, net242424
Long term investments171720
Note receivable - long term------
Other long term assets------
Total assets1,1281,166403
LIABILITIES
Accounts payable3.644.282.47
Accrued expenses171711
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.761.371.33
Other current liabilities, total3.594.172.37
Total current liabilities252718
Total long term debt121213
Total debt131414
Deferred income tax5.455.672.59
Minority interest------
Other liabilities, total------
Total liabilities434533
SHAREHOLDERS EQUITY
Common stock10810881
Additional paid-in capital878871114
Retained earnings (accumulated deficit)100142175
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,0861,122370
Total liabilities & shareholders' equity1,1281,166403
Total common shares outstanding108108108
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.